title: Intracoronary melatonin increases coronary blood flow and cardiac function through β-adrenoreceptors, MT1/MT2 receptors, and nitric oxide in anesthetized pigs.
abstract: Melatonin is involved in the regulation of the cardiovascular system through the modulation of sympathetic function and the nitric oxide (NO)-related pathway and interaction with MT1/MT2 receptors. However, information regarding its direct actions on coronary blood flow and cardiac function is scarce. This study therefore determined the primary in vivo effect of melatonin on cardiac function and perfusion and the involvement of the autonomic nervous system, MT1/MT2 receptors, and NO. In 35 pigs, melatonin infused into the coronary artery at 70 pg for each mL/min of coronary blood flow while preventing changes in heart rate and arterial pressure increased coronary blood flow, dP/dt(max), segmental shortening, and cardiac output by about 12%, 14%, 8%, and 23% of control values (P < 0.05), respectively. These effects were accompanied by an increase in coronary NO release of about 46% (P < 0.05) of control values. The aforementioned responses were graded in a further five pigs. Moreover, the blockade of muscarinic cholinoreceptors (n = 5) and α-adrenoreceptors (n = 5) did not abolish the observed responses to melatonin. After β(1)-adrenoreceptors blocking (n = 5), melatonin failed to affect cardiac function, whereas β(2)-adrenoreceptors (n = 5) and NO synthase inhibition (n = 5) prevented the coronary response and the effect of melatonin on NO release. Finally, all effects were prevented by MT1/MT2 receptor inhibitors (n = 10). In conclusion, melatonin primarily increased coronary blood flow and cardiac function through the involvement of MT1/MT2 receptors, β-adrenoreceptors, and NO release. These findings add new information about the mechanisms through which melatonin physiologically modulates cardiovascular function and exerts cardioprotective effects.
authors.affiliation: Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi del Piemonte Orientale A. Avogadro, Chirurgia Sperimentale, Azienda Ospedaliera Universitaria Maggiore della Carità, Novara, Italy. grossini@med.unipmn.it
authors.forename: Elena
authors.initials: E
authors.lastname: Grossini
authors.forename: Claudio
authors.initials: C
authors.lastname: Molinari
authors.forename: Francesca
authors.initials: F
authors.lastname: Uberti
authors.forename: David A S G
authors.initials: DA
authors.lastname: Mary
authors.forename: Giovanni
authors.initials: G
authors.lastname: Vacca
authors.forename: Philippe P
authors.initials: PP
authors.lastname: Caimmi
mesh_terms: D000758:Anesthesia; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001783:Blood Flow Velocity / Q000187:drug effects; D003326:Coronary Circulation / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D008550:Melatonin / Q000494:pharmacology*; D009124:Muscle Proteins / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism*; D044122:Receptor, Melatonin, MT1 / Q000378:metabolism*; D044123:Receptor, Melatonin, MT2 / Q000378:metabolism*; D011943:Receptors, Adrenergic, beta / Q000378:metabolism*; D013552:Swine
chemical_list: D000975:Antioxidants; D009124:Muscle Proteins; D044122:Receptor, Melatonin, MT1; D044123:Receptor, Melatonin, MT2; D011943:Receptors, Adrenergic, beta; D009569:Nitric Oxide; D008550:Melatonin